- Home
- JMIA vs OCS Comparison
JMIA vs OCS Comparison
Compare JMIA & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMIA
- OCS
- Stock Information
- Founded
- JMIA 2012
- OCS 2003
- Country
- JMIA Germany
- OCS Switzerland
- Employees
- JMIA N/A
- OCS N/A
- Industry
- JMIA Catalog/Specialty Distribution
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- JMIA Consumer Discretionary
- OCS Health Care
- Exchange
- JMIA Nasdaq
- OCS Nasdaq
- Market Cap
- JMIA 1.2B
- OCS 1.0B
- IPO Year
- JMIA 2019
- OCS N/A
- Fundamental
- Price
- JMIA $11.97
- OCS $18.81
- Analyst Decision
- JMIA Strong Buy
- OCS Strong Buy
- Analyst Count
- JMIA 2
- OCS 5
- Target Price
- JMIA $16.50
- OCS $39.80
- AVG Volume (30 Days)
- JMIA 3.4M
- OCS 131.0K
- Earning Date
- JMIA 11-12-2025
- OCS 11-10-2025
- Dividend Yield
- JMIA N/A
- OCS N/A
- EPS Growth
- JMIA N/A
- OCS N/A
- EPS
- JMIA N/A
- OCS N/A
- Revenue
- JMIA $173,224,000.00
- OCS $991,999.00
- Revenue This Year
- JMIA $21.84
- OCS $32.89
- Revenue Next Year
- JMIA $12.09
- OCS $1,043.16
- P/E Ratio
- JMIA N/A
- OCS N/A
- Revenue Growth
- JMIA N/A
- OCS N/A
- 52 Week Low
- JMIA $1.60
- OCS $14.00
- 52 Week High
- JMIA $13.14
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- JMIA 60.18
- OCS 41.08
- Support Level
- JMIA $9.08
- OCS $19.07
- Resistance Level
- JMIA $10.76
- OCS $19.43
- Average True Range (ATR)
- JMIA 0.91
- OCS 0.45
- MACD
- JMIA 0.15
- OCS -0.05
- Stochastic Oscillator
- JMIA 94.50
- OCS 10.75
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.